Professor Charles E. Geyer: neoadjuvant therapy is becoming standard of care for HER2+ breast cancer.

Abstract

Charles E. Geyer Jr. ( Figure 1 ), MD, FACP, is Professor of Medicine in the Division of Hematology, Oncology and Palliative Care, Department of Internal Medicine, at the Virginia Commonwealth University School of Medicine, and he is also an Associate Director for Clinical Research at Virginia Commonwealth University Massey Cancer Center.